Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test

CARLSBAD, Calif.,
Dec. 17, 2019 /PRNewswire/ — Prescient Metabiomics, a subsidiary of
Prescient Medicine Holdings, Inc., and CoreBiome, a wholly owned subsidiary of
OraSure Technologies, Inc., announced today a collaboration to develop a
new test called LifeKit® Prevent, which may represent a microbiome-driven
paradigm shift in colon cancer screening. 

According to the American
Cancer Society, colorectal cancer is the third leading cause of cancer-related
deaths in men and in women, and the second most common cause of cancer deaths
when men and women are combined.  Yet, there is a lack of non-invasive
screening tests that can accurately detect precancerous polyps as effectively
as a colonoscopy.   The current standard of care for colon cancer
prevention is in-clinic screening via colonoscopy, but approximately 1 in 3
patients are not up-to-date with their necessary colon cancer
screenings. Research indicates that early detection of precancerous
adenomas and carcinomas could lead to significantly better patient
outcomes. 

To help address this
issue, Prescient Metabiomics is developing a unique assay for predicting
precancerous adenomas and carcinomas that uses microbial biomarkers as a
diagnostic platform.  Prescient Metabiomics has teamed up with CoreBiome
to utilize shotgun metagenomics DNA sequencing, machine learning and AI-driven
microbiome analytics to accelerate their development pipeline.  

About the Colon Cancer
Microbiome Diagnostics Collaboration
“CoreBiome’s DNA
sequencing platform and innovative bioinformatics methods for data analysis
will be critical for development of the LifeKit® Prevent test,” said
Prescient Medicine CEO Dr. Keri Donaldson. “Prescient Metabiomics
will leverage CoreBiome’s discovery platform to accelerate development and
validation through the FDA’s Breakthrough Devices Program.”

“CoreBiome is
committed to producing ultra-high-quality data at very large scales and helping
customers perform data mining for clinical biomarkers. We are excited to help
Prescient Metabiomics move into the clinic faster by combining our precisely
controlled data generation with Prescient Metabiomics’ customized analysis
algorithms and machine learning,” said CoreBiome CEO Dan Knights.

About Prescient
Metabiomics
Prescient Metabiomics
LLC, a privately held molecular diagnostics company and subsidiary of Prescient
Medicine Holdings, Inc, is an early stage molecular diagnostics company that is
developing in-vitro diagnostics that leverage breakthroughs in next-generation
DNA sequencing, computational systems biology, and human microbiome sciences.
Prescient Metabiomics is a subsidiary of Prescient Medicine Holdings, Inc. To
learn more, visit www.prescientmedicine.com.

About CoreBiome
CoreBiome is a
microbiome genomics company focused on accelerating microbiome discovery for
customers in the pharmaceutical, agriculture, and research communities to
unleash the translational potential of the microbiome. The company’s
proprietary BenchMark™, BoosterShot™, and Core Analysis™ platforms provide fast
and information-rich characterizations of microbial diversity and function,
paired with machine learning and expert analytics. CoreBiome is a wholly-owned
subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), which also owns
DNA Genotek, a leading provider of sampling and stabilization
kits, bringing together an end-to-end solution for robust microbiome
discovery. For more information about CoreBiome, visit http://www.corebiome.com.

SOURCE Prescient
Medicine; CoreBiome